Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
68 hedge funds and large institutions have $122M invested in Adaptimmune Therapeutics in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 18 closing their positions.
3,800% more call options, than puts
Call options by funds: $78K | Put options by funds: $2K
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 12.19% → 12.1% (-0.09%)
12% less funds holding
Funds holding: 77 → 68 (-9)
37% less capital invested
Capital invested by funds: $195M → $122M (-$72.6M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$700K |
| 2 |
KHCM
Kettle Hill Capital Management
New York
|
+$465K |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$387K |
| 4 |
Morgan Stanley
New York
|
+$344K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.1M |
| 3 |
JP Morgan Chase
New York
|
-$859K |
| 4 |
Rafferty Asset Management
New York
|
-$369K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$229K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Tudor Investment Corp
Stamford,
Connecticut
| – | -$26K | -15,232 | Closed |
|
|
EGM
77
Engineers Gate Manager
New York
| – | -$24K | -14,294 | Closed |
|
|
IUHSA
78
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| – | -$13K | -7,434 | Closed |
|
|
VRM
79
Vectors Research Management
New York
| – | -$12K | -7,000 | Closed |
|
|
CSS
80
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$4K | -2,094 | Closed |
|
|
QT
81
Quantbot Technologies
New York
| – | -$3K | -2,000 | Closed |
|
|
BBPWM
82
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| – | -$1K | -759 | Closed |
|
|
JPLA
83
Joseph P. Lucia & Associates
Yorktown Heights,
New York
| – | -$1K | -375 | Closed |
|
ADAP Hedge Fund Activity: Q3 2022 in Review
68 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2022, worth a combined $122M — down 37% from $195M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ADAP and 10 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 20 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $700K. The largest seller was Baillie Gifford & Co, cutting an estimated $1.21M.
- 68 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2022, down from 77 in Q2 2022.
- Funds reported $122M of Adaptimmune Therapeutics stock for Q3 2022, down 37% quarter-over-quarter.
- 10 funds opened new Adaptimmune Therapeutics positions in Q3 2022 and 18 closed out, a net change of -8 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2022 was GSA Capital Partners, an estimated $700K added.
- The largest Adaptimmune Therapeutics seller in Q3 2022 was Baillie Gifford & Co, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2022.